Regeneron
IRB
Details
Info
EMC-IRB-24-030
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma.
A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, A
Factor Xi Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Venous
Thromboembolism After Elective Total Knee Arthroplasty
